Group One Trading
CRVS icon

Group One Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Group One Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$721K Buy
+48,292
New +$670K ﹤0.01% 3170
2026
Q1 		– Sell
-26,667
Closed -$426K – 7821
2025
Q4 		$205K Buy
+26,667
New +$210K ﹤0.01% 4349
2025
Q2 		– Sell
-11,895
Closed -$43.3K – 8016
2025
Q1 		$37.8K Sell
11,895
-40,873
-77% -$193K ﹤0.01% 5371
2024
Q4 		$282K Buy
52,768
+47,208
+849% +$352K ﹤0.01% 3640
2024
Q3 		$29.4K Buy
+5,560
New +$20K ﹤0.01% 5002
2024
Q2 		– Sell
-4,604
Closed -$8.58K – 6840
2024
Q1 		$8.2K Sell
4,604
-32,060
-87% -$67K ﹤0.01% 5974
2023
Q4 		$64.5K Buy
36,664
+9,565
+35% +$14K ﹤0.01% 4851
2023
Q3 		$39.6K Buy
+27,099
New +$57.3K ﹤0.01% 5316
2022
Q4 		– Sell
-7,049
Closed -$6.24K – 7355
2022
Q3 		$6K Sell
7,049
-21,748
-76% -$20.7K ﹤0.01% 6739
2022
Q2 		$29K Buy
28,797
+19,722
+217% +$24.2K ﹤0.01% 6001
2022
Q1 		$15K Sell
9,075
-20,322
-69% -$37.2K ﹤0.01% 6942
2021
Q4 		$71K Buy
+29,397
New +$114K ﹤0.01% 6035
2021
Q3 		– Sell
-7,076
Closed -$20.9K – 8243
2021
Q2 		$19K Sell
7,076
-2,875
-29% -$7.92K ﹤0.01% 7211
2021
Q1 		$31K Buy
9,951
+4,551
+84% +$16.4K ﹤0.01% 6529
2020
Q4 		$19K Buy
5,400
+5,300
+5,300% +$21.3K ﹤0.01% 5542
2020
Q3 		$0 Buy
+100
New +$400 ﹤0.01% 6142

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Group One Trading's CRVS Position: Q2 2026 in Review

Group One Trading opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 48,292 shares worth $721K. The stake represents ﹤0.01% of the portfolio and ranks #3170 among its holdings. This is a return to the name: Group One Trading previously reported a position in CRVS as recently as Q4 2025.

Group One Trading first reported a position in CRVS in Q3 2020 and has held it in 16 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Group One Trading held 48,292 shares of Corvus Pharmaceuticals worth $721K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Group One Trading position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #3170 holding.
  • Group One Trading first reported a position in Corvus Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.